The Health Products Regulatory Authority (HPRA) has launched its Strategic Plan 2026–2029, as it marks 30 years as Ireland’s independent health products regulator. The HPRA says its commitment to protecting people and animals through trusted regulation underpins the organisation’s four strategic goals:

• Strategic Goal 1 — Regulating for the future: supporting timely access to safe and effective health products through leadership, excellence and preparedness;
• Strategic Goal 2 — Digital first, data driven: driving digital transformation to modernise and optimise regulatory activities;
• Strategic Goal 3 — Partnerships, trust and transparency: driving regulatory impact and efficiency through strategic collaboration and partnerships to serve health system needs and strengthen public trust; and
• Strategic Goal 4 — People, capability and culture: inspiring and leading its people to build future-ready, innovative teams committed to excellence in protecting public and animal health.

The HPRA also recently launched its 2025 Annual Report. Key activities included:

• Authorisation of 473 new human medicines following assessment of their safety, quality and effectiveness;
• Issuing 95 authorisations for clinical trials of human medicines under the EU Clinical Trials Regulation;
• Continuing the assessment of veterinary medicines, with 1,966 authorised medicines for animal use on the Irish market at year-end;
• Receipt of 8,565 suspected adverse reaction reports for human medicines; and
• Detention of 763,027 dosage units of falsified and other illegal medicines, while securing the amendment or shutdown of 4,762 websites, e-commerce listings and social media pages associated with the sale of illicit medicinal products.

Both the Annual Report and Strategic Plan are available at hpra.ie.